Efficacy and Safety of APSMNF in the Treatment of Male Androgenetic Alopecia

Starting soon · Phase 3

Conditions studied: Alopecia, Androgenetic

In brief

The purpose of this study is to evaluate the efficacy and safety of APSMNF in the treatment of male androgenetic alopecia.

Key facts

Study ID

NCT07516561

Run by

Apsen Farmaceutica S.A.

People needed

336

Starts

2026-07-07

Expected to finish

2029-08-02

Last updated by the study team

2026-04-13

Who can join

Age: 18 and older, up to 60. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Men aged 18 to 60 years with a clinical diagnosis of androgenetic alopecia ;
• Participants who use an acceptable contraceptive method, or who declare that their partner uses an acceptable contraceptive method, according to the protocol, and who agree to use it throughout the study period.

You may not qualify if…

• History of allergic reactions to any of the active ingredients or to any of the ingredients of teh formulation;
• Participants with a history of alcohol, substance, or illicit drug abuse disorder in the last 2 years;
• Participants with conditions that may affect hair growth or with underlying conditions that cause hair loss, such as a diagnosis of alopecia areata, fibrosing or cicatricial alopecia, or telogen effluvium, the latter being present at the time of screening;
• Participants with concomitant inflammation or other dermatological conditions of the scalp, such as moderate or severe psoriasis or seborrheic dermatitis, and/or active infection and/or keloid formation in the area of alopecia;

Where it is running

• Clinica Geral Investiga Ltda — Campinas, São Paulo, Brazil

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.